RPL34P19

Across TCGA pan-cancer cohorts, RPL34P19 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL34P19’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where RPL34P19 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL34P19 is over-expressed in tumor.

STAD, CHOL, and COAD are the cancer types where RPL34P19 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL34P19 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	All	+0.133	.001	6	view →
CHOL	All	All	+0.171	.020	2	view →
COAD	All	All	+0.080	.016	2	view →
KIRC	All	All	+0.031	.012	2	view →
LUSC	All	II,III,IV	+0.070	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RPL34P19–STAD

Open the STAD breakdown →